Evidence map›Paper›PMID 31671805›Full record

ArticleDiagnostics (Basel, Switzerland)2019

Phospholipids are A Potentially Important Source of Tissue Biomarkers for Hepatocellular Carcinoma: Results of a Pilot Study Involving Targeted Metabolomics.

Erin B Evangelista, Sandi A Kwee, Miles M Sato, Lu Wang, Christoph Rettenmeier, Guoxiang Xie, Wei Jia, Linda L Wong

Open access · goldAbstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Erin B EvangelistaThe Queen's Medical Center, Honolulu, HI 96813, USA. erinbevangelista1998@gmail.com.
Sandi A KweeThe Queen's Medical Center, Honolulu, HI 96813, USA. kwee@hawaii.edu.ORCID 0000-0002-4624-8787
Miles M SatoThe Queen's Medical Center, Honolulu, HI 96813, USA. msato@queens.org.ORCID 0000-0002-1691-5198
Lu WangUniversity of Hawaii Cancer Center, University of Hawaii at Manoa, Honolulu, HI 96813, USA. lwang@cc.hawaii.edu.ORCID 0000-0002-3918-3399
Christoph RettenmeierDepartments of Medicine and Surgery, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI 96813, USA. crettenm@hawaii.edu.
Guoxiang XieUniversity of Hawaii Cancer Center, University of Hawaii at Manoa, Honolulu, HI 96813, USA. gxie@cc.hawaii.edu.
Wei JiaUniversity of Hawaii Cancer Center, University of Hawaii at Manoa, Honolulu, HI 96813, USA. wjia@cc.hawaii.edu.ORCID 0000-0002-3739-8994
Linda L WongUniversity of Hawaii Cancer Center, University of Hawaii at Manoa, Honolulu, HI 96813, USA. hepatoma@aol.com.
University of Hawaiʻi at Mānoa · USQueen's Medical Center · US

Funding

The Role of gp120 on Cardiovascular Disease in People Living with HIVU54MD007601 · NIMHD · UNIVERSITY OF HAWAII AT MANOA · PI Benjamin C. Fogelgren · 2017 to 2026
$59.5M
University of Hawaii Cancer Center CCSGP30CA071789 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI GERTRAUD MASKARINEC · 1996 to 2026
$56.2M
RESEARCH DESIGN AND BIOSTATISTICS COREU54MD007584 · NIMHD · UNIVERSITY OF HAWAII AT MANOA · PI HEDGES, JERRIS ROBERT, MOKUAU, NOREEN · 2012 to 2018
$21.1M
Functional Genomics and Molecular Imaging of Liver Disease and CancerR01CA161209 · NCI · QUEEN'S MEDICAL CENTER · PI KWEE, SANDI ALEXANDER, OKIMOTO, GORDON SHOJI · 2011 to 2016
$2.2M
NCI NIH HHS P30 CA071789NCI NIH HHS R01 CA161209NIH HHS R01CA161209-06NIMHD NIH HHS U54 MD007584NIMHD NIH HHS U54 MD007601
6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) pathogenesis involves the alteration of multiple liver-specific metabolic pathways. We systematically profiled cancer- and liver-related classes of metabolites in HCC and adjacent liver tissues and applied supervised machine learning to compare their potential yield for HCC biomarkers.

methodsTumor and corresponding liver tissue samples were profiled as follows: Bile acids by ultra-performance liquid chromatography (LC) coupled to tandem mass spectrometry (MS), phospholipids by LC-MS/MS, and other small molecules including free fatty acids by gas chromatography-time of flight MS. The overall classification performance of metabolomic signatures derived by support vector machine (SVM) and random forests machine learning algorithms was then compared across classes of metabolite.

resultsFor each metabolite class, there was a plateau in classification performance with signatures of 10 metabolites. Phospholipid signatures consistently showed the highest discrimination for HCC followed by signatures derived from small molecules, free fatty acids, and bile acids with area under the receiver operating characteristic curve (AUC) values of 0.963, 0.934, 0.895, 0.695, respectively, for SVM-generated signatures comprised of 10 metabolites. Similar classification performance patterns were observed with signatures derived by random forests.

conclusionMembrane phospholipids are a promising source of tissue biomarkers for discriminating between HCC tumor and liver tissue.

Indexed as

diagnosishepatocellular carcinomamachine learningmetabolomicsmolecular imagingphospholipidspositron emission tomography

Identifiers

PMID31671805
PMCPMC6963224
OpenAlexW2982543086

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.